Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

详细信息    查看全文

• 作者：Homayoun Zargar^a ; ^&lowast ; ; Kamran Zargar-Shoshtari^b ; ^&lowast ; ; Yair Lotan^c ; ^&lowast ; ; Jay B. Shah^d ; ^&lowast ; ; Bas W. van Rhijn^e ; ^&dagger ; ; Siamak Daneshmand^f ; ^&lowast ; ; Philippe E. Spiess^b ; ^&lowast ; ; Peter Black^a ; ^&lowast ; ; ^{pblack@mail.ubc.ca" class="auth_mail" title="E-mail the corresponding author} ; CollaboratorsAdrian S. Fairey ; Laura S. Mertens ; Simon Horenblas ; Colin P. Dinney ; Maria C. Mir ; Cesar E. Ercole ; Andrew J. Stephenson ; Laura-Maria Krabbe ; Michael S. Cookson ; Niels-Erik Jacobsen ; Daniel A. Barocas ; Joshua Griffin ; Jeff M. Holzbeierlein ; Jeffrey S. Montgomery ; Todd M. Morgan ; Nikhil Vasdev ; Andrew C. Thorpe ; Jonathan Aning ; Evan Y. Yu ; Jonathan L. Wright ; Evanguelos Xylinas ; Nicholas J. Campain ; Farshad Pourmalek ; John S. McGrath ; Wassim Kassouf ; Marc A. Dall'Era ; Jo-An Seah ; Srikala S. Sridhar ; Pranav Sharma ; Shahrokh F. Shariat ; Scott North ; Petros Grivas ; Nilay Gandhi ; Trinity J. Bivalacqua
• 关键词：neoadjuvant therapy ; drug therapy ; cystectomy ; urinary bladder neoplasms
• 刊名：The Journal of Urology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：195
• 期：4
• 页码：886-893
• 全文大小：589 K

文摘

We assessed survival dependent on pathological response after neoadjuvant chemotherapy in a large multicenter patient cohort, with a particular focus on the difference between the absence of residual cancer (pT0) and the presence of only nonmuscle invasive residual cancer (pTa, pTis, pT1).

Materials and Methods

We retrospectively reviewed records of patients with urothelial cancer who received neoadjuvant chemotherapy and underwent radical cystectomy at 19 contributing institutions from 2000 to 2013. Patients with cT2-4aN0M0 and eventual pN0 disease were selected for this analysis. Estimated overall survival was compared between patients with pT0 and pTa/Tis/T1 disease. A multivariable Cox proportional hazards regression model for overall survival was generated to evaluate hazard ratios for variables of interest.

Results

Of 1,543 patients treated with neoadjuvant chemotherapy and radical cystectomy during the study period 257 had pT0N0 and 207 had pTa/Tis/T1N0 disease. The Kaplan-Meier mean estimates of overall survival for pT0 and pTa/Tis/T1 cases were 186.7 months (95% CI 145.9–227.6, median 241.1) and 138 months (95% CI 118.2–157.8, median 187.4), respectively (p=0.58). In the Cox proportional hazards regression model for overall survival pTa/Tis/T1N0 status (HR 0.36, 95% CI 0.23–0.67) and pT0N0 status (HR 0.28, 95% CI 0.17–0.47) compared to pT2N0 pathology, positive surgical margin (HR 1.75, 95% CI 1.07–2.86), and receiving a methotrexate, vinblastine, doxorubicin and cisplatin regimen compared to an “other” regimen (HR 0.45, 95% CI 0.27–0.76) were predictors of overall survival.

Conclusions

pTa/Tis/T1N0 and pT0N0 stage on the final cystectomy specimen are strong predictors of survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. We did not discern a statistically significant difference in overall survival when comparing these 2 end points.